News

EIT Jumpstarter opens for early-stage innovators

Published on | 1 hour ago

Programmes
Climate, Energy, Mobility EIT

EIT Jumpstarter is designed for early-stage teams that want to turn an idea into a business. It is a seven-month pre-acceleration programme for early-stage innovators from more than 28 countries and territories. Teams can apply in seven thematic categories and compete for a first prize of up to €10,000, with several additional special prizes of €2,500. The programme also includes coaching, in-person training, travel support and links with innovation hubs across Europe.

Applicants (at least 1 participating team member) must hold citizenship from one of the following countries or regions:

  • EU Member States: Bulgaria, Croatia, Cyprus, Czechia, Estonia, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Poland, Portugal, Romania, Slovenia, Slovakia and Spain.

  • EU Outermost Regions: Guadeloupe, French Guiana, Réunion, Martinique, Mayotte and Saint-Martin (France); the Azores and Madeira (Portugal); and the Canary Islands (Spain).

  • Horizon Europe Associated Countries and Territories: Albania, Armenia, Bosnia and Herzegovina, *Kosovo, Moldova, Montenegro, North Macedonia, Serbia, Ukraine and Türkiye.

Applicants can submit ideas in seven categories: Food & Agritech, Healthcare, Energy & Renewables, Smart Cities & Urban Mobility, Advanced and Green Manufacturing, Metals, Minerals and Industrial Side Streams, and a Malta-focused strand supporting startups and innovations.

Interested applicants can review the eligibility rules, thematic scope and application guidance on the programme website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1838 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.